Organic Potash Corporation announces an amendment to its $100,000.00 CDN Private Placement Financing
TORONTO, June 21, 2018 (GLOBE NEWSWIRE) -- Organic Potash Corporation (CNSX:OPC) (“OPC” or the “Corporation”) announced today that the non-brokered private placement to raise gross proceeds of up to 100,000 dollars at a price of $0.01 per share to a total of 10,000,000 common shares was amended to raise gross proceeds of up to 110,000 dollars at a price of $0.02 per share to a total of 5,500,000 common shares.
The offering in its amended form is closed.
All proceeds from the offering will be used to maintain the Corporation’s administrative annual expenses and other ongoing corporate matters.
About Organic Potash Corporation
Through its proprietary patented technology, Organic Potash Corporation produces 99%+ pure potassium carbonate (potash) from the ash of agricultural waste, in particular, cocoa husks. The purity of the company’s potassium carbonate will allow Organic Potash Corporation to target multiple industries including the Agricultural and Pharmaceutical industry. Organic Potash Corporation is headquartered in Toronto, Ontario and its shares trade on the Canadian Securities Exchange under the trading symbol “OPC”. For further information, please visit the company website at www.organicpotash.com.
For further information please contact:
Mrs. Heather Welner
President and CEO
Organic Potash Corporation
Tel: (905) 452-8060
E-mail: heather.welner@organicpotash.com
Web: www.organicpotash.com
Forward-Looking Statements
Information set forth in this news release may involve forward-looking statements under applicable securities laws. The forward-looking statements contained herein are expressly qualified in their entirety by this cautionary statement. The forward-looking statements included in this document are made as of the date of this document and the Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities legislation. Although Management believes that the expectations represented in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither CNSX Exchange nor its Regulation Services Provider (as that term is defined in the policies of the CNSX) accepts responsibility for the adequacy or accuracy of this release.
© 2018 GlobeNewswire, Inc. All Rights Reserved.
Regeneron Pharmaceuticals' (Nasdaq: REGN) REGEN-COV2 is First Antibody Cocktail for COVID-19 to Receive FDA Emergency Use Authorization
